196 related articles for article (PubMed ID: 37921427)
1. Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma.
Hou K; Xu X; Ge X; Jiang J; Ouyang F
Biofactors; 2024; 50(2):250-265. PubMed ID: 37921427
[TBL] [Abstract][Full Text] [Related]
2. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Harding JJ
Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
[TBL] [Abstract][Full Text] [Related]
6. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; 21(6):. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for hepatocellular carcinoma.
Zongyi Y; Xiaowu L
Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
12. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
Moreno-Cubero E; Larrubia JR
World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
[TBL] [Abstract][Full Text] [Related]
13. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
[TBL] [Abstract][Full Text] [Related]
14. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Llopiz D; Ruiz M; Villanueva L; Iglesias T; Silva L; Egea J; Lasarte JJ; Pivette P; Trochon-Joseph V; Vasseur B; Dixon G; Sangro B; Sarobe P
Cancer Immunol Immunother; 2019 Mar; 68(3):379-393. PubMed ID: 30547218
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding JJ; El Dika I; Abou-Alfa GK
Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.
Roudi R; D'Angelo A; Sirico M; Sobhani N
Int Immunopharmacol; 2021 Dec; 101(Pt A):108322. PubMed ID: 34735916
[TBL] [Abstract][Full Text] [Related]
19. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]